Cwm LLC owns $38,000 in Quanterix Co. (NASDAQ:QTRX)

Cwm LLC reduced its holdings in Quanterix Co. (NASDAQ:QTRX – Free Report ) by 97.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,882 shares of the company’s stock after selling 132,907 shares during the quarter. Cwm LLC’s holdings in Quanterix were worth $38,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the business. AJOVista LLC purchased a new position in Quanterix in the 4th quarter valued at approximately $81,000. Picton Mahoney Asset Management bought a new position in Quanterix in the fourth quarter valued at $139,000. Comerica Bank boosted its holdings in Quanterix by 44,205.6% in the first quarter. Comerica Bank now owns 7,975 shares of the company’s stock worth $188,000 after purchasing an additional 7,957 shares during the period. Quest Partners LLC bought a new stake in shares of Quanterix in the 4th quarter valued at approximately $240,000. Finally, Janney Capital Management LLC purchased a new stake in shares of Quanterix in the first quarter valued at approximately $259,000. Institutional investors own 86.48% of the company’s shares.

Quanterix stock falls 0.5%

NASDAQ:QTRX opened at $13.15 on Thursday. Quanterix Co. has a 12-month low of $10.50 and a 12-month high of $29.70. The company has a fifty day moving average of $13.48 and a 200 day moving average of $18.23. The firm has a market cap of $503.25 million, a P/E ratio of -13.70 and a beta of 1.39.

Quanterix (NASDAQ:QTRX – Get Your Free Report ) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.02). The company had revenue of $34.38 million during the quarter, compared to the consensus estimate of $34.19 million. Quanterix had a negative net margin of 30.71% and a negative return on equity of 11.52%. During the same period last year, the company posted ($0.16) earnings per share. On average, analysts anticipate that Quanterix Co. will post -0.88 EPS for the current fiscal year.

Analyst upgrades and downgrades

Several brokerages have recently commented on QTRX. Scotiabank cut their price target on Quanterix from $32.00 to $28.00 and set a “sector outperform” rating on the stock in a report on Monday, August 12th. TD Cowen reduced their price objective on shares of Quanterix from $17.00 to $15.00 and set a “hold” rating on the stock in a research note on Friday, August 9th. Goldman Sachs Group cut their price target on shares of Quanterix from $35.00 to $24.00 and set a “buy” rating for the company in a research note on Tuesday, July 9th. Finally, Canaccord Genuity Group decreased their target price on shares of Quanterix from $32.00 to $25.00 and set a “buy” rating on the stock in a report on Monday, April 29th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Quanterix currently has an average rating of “Moderate Buy” and an average target price of $24.80, according to MarketBeat.com.

Read the latest stock analysis on QTRX

About Quanterix

(Free Report)

Quanterix Corporation, a life sciences company, is engaged in the development and commercialization of digital immunoassay platforms that advance precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa and the Asia Pacific regions. The company offers the HD-X instrument, a protein detection platform; and SR-X instrument that allows researchers to apply Simoa detection in a wide range of applications.

Featured stories

Want to see what other hedge funds own QTRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trading for Quanterix Co. (NASDAQ:QTRX – Free Report).

Get news and reviews for Quanterix Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Quanterix and related companies with MarketBeat.com’s FREE daily email newsletter.